Opioid receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

  • Anna Borsodi Hungarian Academy Of Sciences
  • Michael Bruchas Washington University
  • Girolamo Caló University of Ferrara
  • Charles Chavkin University of Washington Sch Med
  • MacDonald J. Christie University of Sydney
  • Olivier Civelli University of California at Irvine
  • Mark Connor Macquarie University https://orcid.org/0000-0003-2538-2001
  • Brian M. Cox Uniformed Services University
  • Lakshmi A. Devi Mount Sinai School of Medicine
  • Christopher Evans University of California Los Angeles
  • Volker Höllt Otto-von-Guericke University
  • Graeme Henderson University of Bristol
  • Stephen Husbands University of Bath
  • Eamonn Kelly University of Bristol
  • Brigitte Kieffer Université de Strasbourg
  • Ian Kitchen University of Surrey
  • Mary-Jeanne Kreek Rockefeller University
  • Lee-Yuan Liu-Chen Temple University
  • Dominique Massot Université de Strasbourg
  • Jean-Claude Meunier Institute of Pharmacology and Structural Biology
  • Philip S. Portoghese University of Minnesota
  • Stefan Schulz Friedrich Schiller University
  • Toni S. Shippenberg National Institutes of Health
  • Eric J. Simon New York University
  • Lawrence Toll Florida Atlantic University
  • John R. Traynor University of Michigan
  • Hiroshi Ueda Nagasaki Univ Grad Biomed Sci
  • Yung H. Wong Hong Kong University of Science and Technology
  • Nurulain Zaveri Astraea Therapeutics, LLC
  • Andreas Zimmer University of Bonn


Opioid and opioid-like receptors are activated by a variety of endogenous peptides including [Met]enkephalin (met), [Leu]enkephalin (leu), β-endorphin (β-end), α-neodynorphin, dynorphin A (dynA), dynorphin B (dynB), big dynorphin (Big dyn), nociceptin/orphanin FQ (N/OFQ); endomorphin-1 and endomorphin-2 are also potential endogenous peptides. The Greek letter nomenclature for the opioid receptors, μ, δ and κ, is well established, and NC-IUPHAR considers this nomenclature appropriate, along with the symbols spelled out (mu, delta, and kappa), and the acronyms, MOP, DOP, and KOP. [116, 96, 88]. The human N/OFQ receptor, NOP, is considered 'opioid-related' rather than opioid because, while it exhibits a high degree of structural homology with the conventional opioid receptors [282], it displays a distinct pharmacology. Currently there are numerous clinically used drugs, such as morphine and many other opioid analgesics, as well as antagonists such as naloxone, however only for the μ receptor.
How to Cite
Borsodi, A., Bruchas, M., Caló, G., Chavkin, C., Christie, M. J., Civelli, O., Connor, M., Cox, B. M., Devi, L. A., Evans, C., Höllt, V., Henderson, G., Husbands, S., Kelly, E., Kieffer, B., Kitchen, I., Kreek, M.-J., Liu-Chen, L.-Y., Massot, D., Meunier, J.-C., Portoghese, P. S., Schulz, S., Shippenberg, T. S., Simon, E. J., Toll, L., Traynor, J. R., Ueda, H., Wong, Y. H., Zaveri, N. and Zimmer, A. (2019) “Opioid receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database”, IUPHAR/BPS Guide to Pharmacology CITE, 2019(4). doi: 10.2218/gtopdb/F50/2019.4.